Substance Dependence — A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
Citation(s)
A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward